Covance Reports Second Quarter Net Revenue Growth of 8.0% to $639 Million, Pro Forma EPS Growth of 21.5% to $0.95 and Adjusted Net Orders of $773 Million

PRINCETON, N.J.July 29, 2014 -- Covance Inc. (NYSE: CVD) today reported results for its second quarter ended June 30, 2014.  Net revenue was $639 million, representing 8.0% growth from the second quarter of 2013.  On a GAAP basis, the company reported earnings of $0.29 per diluted share in the second quarter.  The company reported pro forma earnings per diluted share of $0.95, up 21.5% over the second quarter of 2013. Pro forma results exclude asset impairment charges totaling $52.6 million, or $0.61 per share, and charges associated with restructuring and other cost reduction actions totaling $4.2 million or $0.05 per share.

"In the second quarter, a stronger-than-expected performance in Early Development and continued strong growth in central laboratories more than offset lower-than-expected growth in clinical development, leading to year-on-year revenue growth of 8%, expanded pro forma operating margins of 11.9%, and a 21.5% year-on-year increase in pro forma EPS," said Joe Herring, Chairman and Chief Executive Officer. "Commercial performance strengthened from the first quarter, with second quarter adjusted net orders of $773 million resulting in an adjusted net book-to-bill of 1.21 to 1.  

"In Early Development, revenue of $231.2 million grew 7.7% year-on-year and 5.9% sequentially while pro forma operating margin increased 200 basis points year-on-year and 360 basis points sequentially to 13.3%. These better-than-expected results were driven by growth in demand for toxicology and pharmaceutical chemistry services, and continued strength in clinical pharmacology services.

"Late-Stage Development second quarter revenue grew 8.1% year-on-year to $408.3 million and pro forma operating margins were 22.1%, up 70 basis points from a year ago, but down 110 basis points from the strong first quarter margins on higher IT spending.  Central laboratories and clinical development grew 11% and 4%, respectively, and market access services resumed year-on-year growth.

"Looking ahead, we expect increases of a few cents in earnings per share in both the third and fourth quarter. We now expect 2014 revenue growth of 6% to 8% and pro forma diluted earnings per share of $3.78 to $3.92(excluding the gain on sale, costs associated with our restructuring activities, asset impairment charges and assuming foreign exchange rates remain at June 30, 2014 levels)."

Consolidated Results

($ in millions except EPS)

2Q14

2Q13

Change

YTD14

YTD13

Change

Total Revenues

$687.1

$644.0

 

$1,353.4

$1,278.3

 

Less: Reimbursable Out-of-Pockets 

$47.6

$51.7

 

$93.9

$105.8

 

Net Revenues

$639.5

$592.3

8.0%

$1,259.5

$1,172.5

7.4%

Operating Income

$19.3

$51.5

(62.6%)

$86.2

$99.8

(13.6%)

   Operating Margin

3.0%

8.7%

 

6.8%

8.5%

 

Net Income

$16.9

$41.0

(58.7%)

$67.8

$89.2

(24.0%)

Diluted Earnings per Share

$0.29

$0.72

(59.2%)

$1.17

$1.58

(25.5%)

Restructuring Costs

($4.2)

($6.0)

 

($8.3)

($12.2)

 

Asset Impairments

($52.6)

-

 

($52.6)

-

 

Operating Income, excluding items*

$76.0

$57.5

32.2%

$147.1

$ 111.9

31.4%

  Operating Margin, excluding items*

11.9%

9.7%

 

11.7%

9.5%

 

Gain on Sale of Business/Investment

-

$0.7

 

$1.6

$16.4

 

Net Income, excluding items*

$54.7

$44.5

22.9%

$107.0

$86.8

23.3%

Diluted EPS, excluding items*

$0.95

$0.78

21.5%

$1.85

$1.53

20.8%

* See attached pro forma income statements for reconciliation of 2014 and 2013 GAAP to pro forma amounts. 

Operating Segment Results

Early Development

 

($ in millions)

2Q14

2Q13

Change

YTD14

YTD13

Change

Net Revenues

$231.2

$214.6

7.7%

$449.4

$421.9

6.5%

Operating Income (Loss)

($22.4)

$21.9

n/c

($2.9)

$38.4

n/c

Operating Margin

(9.7%)

10.2%

 

(0.7%)

9.1%

 

Restructuring Costs

($0.7)

($2.3)

 

($2.3)

($5.9)

 

Asset Impairments

($52.6)

   

($52.6)

   

Operating Income, excluding items

$30.8

$24.2

27.1%

$51.9

$44.3

17.1%

Operating Margin, excluding items

13.3%

11.3%

 

11.5%

10.5%

 

 

The Early Development segment includes preclinical toxicology, analytical chemistry, clinical pharmacology, discovery support, and research products.  Net revenues in the second quarter of 2014 increased 7.7% year-on-year to $231.2 million, as strong growth in clinical pharmacology, toxicology and pharmaceutical chemistry services more than offset a decline in discovery support and the impact of the sale of our Seattle genomics laboratory. In the quarter, foreign exchange favorably impacted year-on-year revenue growth by 250 basis points. Sequentially, revenue increased by $13.0 million from the first quarter on continued strength in clinical pharmacology and a rebound in toxicology and pharmaceutical chemistry services.

GAAP operating loss in the second quarter of 2014 was $22.4 million, and included non-cash asset impairments totaling $52.6 million, associated primarily with the company's Chandler, Arizona facility, and $0.7 million in costs associated with our restructuring and cost reduction actions.  This compares to operating income of $21.9 million in the second quarter of 2013, which included charges associated with restructuring and other cost reduction actions of $2.3 million.  Pro forma operating income, excluding these items, was $30.8 million in the second quarter of this year, a 27.1% increase from the second quarter of 2013. Pro forma operating margins were 13.3% in the second quarter of this year, versus 11.3% in the second quarter of 2013 and 9.7% last quarter.  The sequential increase in pro forma operating income was driven by the rebound in toxicology and pharmaceutical chemistry services and continued strength in clinical pharmacology. 

Late-Stage Development                

($ in millions)

2Q14

2Q13

Change

YTD14

YTD13

Change

Net Revenues

$408.3

$377.7

8.1%

$810.1

$750.6

7.9%

Operating Income

$87.1

$79.5

9.5%

$180.1

$162.4

10.9%

Operating Margin

21.3%

21.0%

 

22.2%

21.6%

 

Restructuring Costs

($3.1)

($1.4)

 

($3.4)

($3.3)

 

Operating Income, excluding items

$90.2

$80.9

11.5%

$183.5

$165.7

10.7%

Operating Margin, excluding items

22.1%

21.4%

 

22.7%

22.1%

 

The Late-Stage Development segment includes central laboratory, Phase IIb-IV clinical development, and market access services.  Net revenues for the second quarter of 2014 grew 8.1% year-on-year to $408.3 million, a sequential increase of $6.4 million from the first quarter level. In the quarter, foreign exchange favorably impacted year-over-year revenue growth by 270 basis points. Year-over-year growth was primarily driven by central laboratories and market access services. Sequentially, growth in central laboratories more than offset a decline in clinical development services.

Operating income for the second quarter was $87.1 million on a GAAP basis and included $3.1 million in costs associated with our restructuring and cost reduction actions.  On a pro forma basis, operating income was $90.2 million, up 11.5% year-over-year led by clinical development and central laboratory services, and down from the $93.3 million delivered last quarter. Pro forma operating margins expanded to 22.1% for the second quarter of 2014, up from 21.4% last year, but down from the very strong 23.2% last quarter on increased IT operating expense.    

Corporate Information

The company reported second quarter adjusted net orders of $773 million. Backlog at June 30, 2014 was $6.92 billion compared to $6.90 billion at March 31, 2014 and $6.73 billion at June 30, 2013. Backlog was negatively impacted in the quarter by a $23 million foreign exchange headwind. 

Corporate expenses totaled $45.4 million in the second quarter of 2014 (including $0.4 million in restructuring and other cost reduction actions) versus $45.6 million last quarter (including $2.3 million in restructuring and other cost reduction actions) and $49.9 million (including $2.3 million in restructuring and other cost reduction actions) in the second quarter of 2013. On a pro forma basis, excluding these costs, corporate spending was$45.0 million or 7.0% of net revenue in the second quarter of 2014 versus $43.4 million or 7.0% of net revenue last quarter and $47.6 million or 8.0% of net revenue in the second quarter of 2013.  The sequential increase was driven by higher IT operating expense while the decline from last year was driven by higher incentive compensation expense in the 2013 period. 

Cash, cash equivalents, and short-term investments at June 30, 2014 were $648 million compared to $660 million at March 31, 2014 and $446 million at June 30, 2013.  Free cash flow (defined as operating cash flow less capital expenditures) for the second quarter of 2014 was $30 million, consisting of operating cash flow of $68 million less capital expenditures of $38 million.  Year-to-date free cash flow was negative $76 million, consisting of operating cash flow of negative $3 million less capital expenditures of $73 million.  We continue to expect full year free cash flow of approximately $130 million, net of capital expenditures of approximately $160 million.  The free cash flow target for 2014 assumes net DSO at 40 days at December 31, 2014.

In the second quarter, the company repurchased $75 million of its common stock. Debt outstanding increased to $290 million, up $40 million from March 31, 2014. 

Net Days Sales Outstanding (DSO) were 45 days at June 30, 2014 compared to 38 days at March 31, 2014 and 48 days at June 30, 2013.

The pro forma effective tax rate in the second quarter was 23.7% and is expected to be approximately 24% for the remainder of 2014.

The Company's investor conference call will be webcast on July 30 at 9:30 am ET.  Management's commentary and presentation slides will be available through www.covance.com.  

Covance, the world's most comprehensive drug development company and a leader in nutritional analysis, is dedicated to advancing healthcare and delivering Solutions Made Real.  The company, headquartered inPrinceton, New Jersey, has annual revenues greater than $2.4 billion and more than 12,500 employees located in over 60 countries. Information on Covance's solutions, recent press releases, and SEC filings can be obtained through its website at www.covance.com.

Statements contained in this press release, which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue and earnings growth and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.  These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss or delay of large studies, risks associated with acquisitions and investments, the Company's ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, testing mix and geographic mix of kit receipts in central laboratories, fluctuations in currency exchange rates, the realization of savings from the Company's announced restructuring actions, the cost and pace of completion of our information technology projects and the realization of benefits therefrom, and other factors described in the Company's filings with theSecurities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.  The Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.

Financial Exhibits Follow

COVANCE INC.

 

CONSOLIDATED INCOME STATEMENTS

 

FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2014 AND 2013

 

(Dollars in thousands, except per share data)

 

(UNAUDITED)

                   
   

Three Months Ended June 30

 

Six Months Ended June 30

 
   

2014

 

2013

 

2014

 

2013

 
               

Net revenues

 

$          639,456

 

$           592,298

 

$   1,259,508

 

$   1,172,497

 

Reimbursable out-of-pocket expenses

 

47,652

 

51,678

 

93,888

 

105,814

 

     Total revenues

 

687,108

 

643,976

 

1,353,396

 

1,278,311

 
                   

Costs and expenses:

                 

  Cost of revenue

 

446,659

 

419,115

 

879,212

 

830,459

 

  Reimbursable out-of-pocket expenses

 

47,652

 

51,678

 

93,888

 

105,814

 

  Selling, general and administrative

 

87,324

 

90,177

 

174,606

 

179,396

 

  Depreciation and amortization

 

33,645

 

31,496

 

66,974

 

62,881

 

  Impairment charges

 

52,564

 

-

 

52,564

 

-

 

        Total costs and expenses

 

667,844

(a)

592,466

(c)

1,267,244

(b)

1,178,550

(d)

                   

Income from operations

 

19,264

(a)

51,510

(c)

86,152

(b)

99,761

(d)

                   

Other expense (income), net:

                 

  Interest expense, net

 

2,809

 

1,004

 

5,257

 

1,875

 

  Foreign exchange transaction loss, net

 

1,542

 

694

 

1,944

 

1,029

 

  Gain on sale of business

 

-

 

-

 

(1,648)

 

-

 

  Gain on sale of investments

 

-

 

(707)

 

-

 

(16,400)

 

        Other expense (income), net

 

4,351

 

991

(c)

5,553

(b)

(13,496)

(d)

                   

Income before taxes

 

14,913

(a)

50,519

(c)

80,599

(b)

113,257

(d)

                   

Tax (benefit) expense

 

(2,024)

(a)

9,525

(c)

12,846

(b)

24,097

(d)

                   

Net income

 

$            16,937

(a)

$            40,994

(c)

$        67,753

(b)

$        89,160

(d)

                   

Basic earnings per share

 

$                0.30

(a)

$                0.75

(c)

$            1.22

(b)

$            1.64

(d)

                   

Weighted average shares outstanding - basic

 

55,556,218

 

54,662,093

 

55,618,752

 

54,434,563

 
                   

Diluted earnings per share

 

$                0.29

(a)

$                0.72

(c)

$            1.17

(b)

$            1.58

(d)

                   

Weighted average shares outstanding - diluted

 

57,549,868

 

56,880,115

 

57,769,847

 

56,598,936

 
                   
                   

(a) Three months ended June 30, 2014 includes, as applicable, $52,564 in asset impairment charges ($34,866 net of tax) and $4,198 in charges associated with restructuring and other cost reduction actions ($2,864 net of tax).

 
                   

(b) Six months ended June 30, 2014 includes, as applicable, $52,564 in asset impairment charges ($34,866 net of tax), $8,336 in charges associated with restructuring and other cost reduction actions ($5,451 net of tax) and $1,648 gain on sale of certain assets of Genomics Laboratory ($1,033 net of tax).

 
   

(c) Three months ended June 30, 2013 includes, as applicable, $6,013 in charges associated with restructuring and other cost reduction actions ($3,942 net of tax), and $707 gain on sale of investment ($460 net of tax).

 
                   

(d) Six months ended June 30, 2013 includes, as applicable, $12,183 in charges associated with restructuring and other cost reduction actions ($8,289 net of tax), and $16,400 gain on sale of investments ($10,654 net of tax).

 
                   
                   
                   

Excluding the impact of impairment charges, charges associated with restructuring and other cost reduction actions, gain on sale of business and gain on sale of investments, as applicable:

 

 
                   
                   

Income from operations

 

$            76,026

 

$            57,523

 

$      147,052

 

$      111,944

 
                   

Taxes on income

 

$            17,008

 

$            11,349

 

$        32,814

 

$        22,245

 
                   

Net income 

 

$            54,667

 

$            44,476

 

$      107,037

 

$        86,795

 
                   

Basic earnings per share

 

$                0.98

 

$                0.81

 

$            1.92

 

$            1.59

 
                   

Diluted earnings per share

 

$                0.95

 

$                0.78

 

$            1.85

 

$            1.53

 

 

 

COVANCE INC.

 

CONSOLIDATED BALANCE SHEETS

 

JUNE 30, 2014 and DECEMBER 31, 2013

 

(Dollars in thousands)

           
           
     

June 30

 

December 31

     

2014

 

2013

     

(UNAUDITED)

   

ASSETS

       

Current Assets:

       
 

Cash & cash equivalents

 

$       536,009

 

$      617,686

 

Short-term investments

 

111,844

 

111,359

 

Accounts receivable, net

 

355,272

 

331,815

 

Unbilled services

 

162,396

 

141,707

 

Inventory

 

52,429

 

48,257

 

Deferred income taxes

 

54,211

 

51,543

 

Prepaid expenses and other current assets

 

233,574

 

201,621

 

    Total Current Assets

 

1,505,735

 

1,503,988

           

Property and equipment, net

 

875,977

 

913,612

Goodwill

 

118,581

 

109,820

Other assets

 

38,351

 

29,168

 

    Total Assets

 

$    2,538,644

 

$   2,556,588

           

LIABILITIES and STOCKHOLDERS' EQUITY

       

Current Liabilities:

       
 

Accounts payable

 

$         83,048

 

$        59,713

 

Accrued payroll and benefits

 

123,122

 

170,806

 

Accrued expenses and other current liabilities

 

111,889

 

153,808

 

Unearned revenue

 

202,560

 

240,398

 

Short-term debt 

 

40,000

 

-

 

Income taxes payable

 

20,572

 

7,952

 

    Total Current Liabilities

 

581,191

 

632,677

           

Long-term debt

 

250,000

 

250,000

Deferred income taxes

 

13,402

 

32,035

Other liabilities

 

78,378

 

76,630

 

    Total Liabilities

 

922,971

 

991,342

           

Stockholders' Equity:

       
 

Common stock

 

824

 

809

 

Paid-in capital

 

943,652

 

859,535

 

Retained earnings

 

1,847,586

 

1,779,833

 

Accumulated other comprehensive income

 

37,708

 

25,746

 

Treasury stock

 

(1,214,097)

 

(1,100,677)

 

    Total Stockholders' Equity

 

1,615,673

 

1,565,246

 

    Total Liabilities and Stockholders'  Equity

 

$    2,538,644

 

$   2,556,588

           

 

 

COVANCE INC.

 

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

FOR THE SIX MONTHS ENDED JUNE 30, 2014 AND 2013

 

(Dollars in thousands)

 

(UNAUDITED)

         
   

Six Months Ended June 30

         
   

2014

 

2013

Cash flows from operating activities:

       

  Net income

 

$          67,753

 

$          89,160

  Adjustments to reconcile net income to net cash used in

       

    operating activities:

       

    Depreciation and amortization

 

66,974

 

62,881

    Non-cash impairment charges

 

52,564

 

-

    Non-cash compensation expense associated with employee benefit

       

       and stock compensation plans

 

19,726

 

19,311

    Deferred income tax benefit

 

(21,571)

 

(5,712)

    Gain on sale of business

 

(1,648)

 

-

    Gain on sale of investments

 

-

 

(16,400)

    Loss on disposal of property and equipment

 

333

 

375

    Changes in operating assets and liabilities, net of businesses sold

       

       and acquired:

       

       Accounts receivable

 

(22,552)

 

(57,095)

       Unbilled services

 

(20,575)

 

(17,467)

       Inventory

 

(5,029)

 

1,323

       Accounts payable

 

23,288

 

18,312

       Accrued liabilities

 

(91,862)

 

(45,470)

       Unearned revenue

 

(37,867)

 

(14,095)

       Income taxes

 

17,504

 

6,736

       Other assets and liabilities, net

 

(49,562)

 

(44,441)

Net cash used in operating activities

 

(2,524)

 

(2,582)

         

Cash flows from investing activities:

       

  Capital expenditures

 

(73,023)

 

(68,433)

  Acquisition of business, net of cash acquired

 

(8,403)

 

-

  Proceeds from sale of business

 

8,429

 

-

  Proceeds from sale of investments

 

-

 

17,781

  Other, net

 

-

 

394

Net cash used in investing activities

 

(72,997)

 

(50,258)

         

Cash flows from financing activities:

       

  Net borrowings under revolving credit facility

 

40,000

 

5,000

  Stock issued under option plans

 

59,118

 

40,226

  Purchase of treasury stock

 

(113,420)

 

(27,118)

Net cash (used in) provided by financing activities

 

(14,302)

 

18,108

Effect of exchange rate changes on cash

 

8,146

 

(12,492)

Net change in cash and cash equivalents

 

(81,677)

 

(47,224)

         

Cash and cash equivalents, beginning of period

 

617,686

 

492,824

         

Cash and cash equivalents, end of period

 

$        536,009

 

$        445,600

         

 

 

COVANCE INC.

 

GAAP to Pro Forma Reconciliation

 

Q2 2014

 

(Dollars in thousands, except per share data)

 

(UNAUDITED)

               
     

Adjustments

 
 

GAAP

 

 Restructuring

and Other Cost

Reduction

 Activities (1)

 

Other
Items (2)

 

Pro Forma

               

Net revenues

$      639,456

         

$      639,456

Reimbursable out-of-pocket expenses

47,652

         

47,652

     Total revenues

687,108

 

-

 

-

 

687,108

               

Costs and expenses:

             

  Cost of revenue

446,659

         

446,659

  Reimbursable out-of-pocket expenses

47,652

         

47,652

  Selling, general and administrative

87,324

 

(3,784)

     

83,540

  Depreciation and amortization

33,645

 

(414)

     

33,231

  Impairment charges

52,564

     

(52,564)

 

-

        Total costs and expenses

667,844

 

(4,198)

 

(52,564)

 

611,082

               

Income from operations

19,264

 

4,198

 

52,564

 

76,026

               

Other expense, net:

             

  Interest expense, net

2,809

         

2,809

  Foreign exchange transaction loss, net

1,542

         

1,542

        Other expense, net

4,351

 

-

 

-

 

4,351

               

Income before taxes

14,913

 

4,198

 

52,564

 

71,675

               

Tax (benefit) expense

(2,024)

 

1,334

 

17,698

 

17,008

               

Net income 

$        16,937

 

$            2,864

 

$          34,866

 

$        54,667

               

Basic earnings per share

$            0.30

 

$              0.05

 

$              0.63

 

$            0.98

               

Weighted average shares outstanding - basic

55,556,218

 

55,556,218

 

55,556,218

 

55,556,218

               

Diluted earnings per share

$            0.29

 

$              0.05

 

$              0.61

 

$            0.95

               

Weighted average shares outstanding - diluted

57,549,868

 

57,549,868

 

57,549,868

 

57,549,868

               
               

(1) Represents costs incurred to better align capacity to preclinical market demand and reduce overall cost structure.

(2) Represents asset impairment charges.

 

 

 

COVANCE INC.

 

GAAP to Pro Forma Reconciliation

 

Q2 2013

 

(Dollars in thousands, except per share data)

       

(UNAUDITED)

               
     

Adjustments

 
 

GAAP

 

 Restructuring

and Other Cost

Reduction

Activities (1)

 

Other
Items (2)

 

Pro Forma

               

Net revenues

$     592,298

         

$     592,298

Reimbursable out-of-pocket expenses

51,678

         

51,678

     Total revenues

643,976

 

-

 

-

 

643,976

               

Costs and expenses:

             

  Cost of revenue

419,115

         

419,115

  Reimbursable out-of-pocket expenses

51,678

         

51,678

  Selling, general and administrative

90,177

 

(5,428)

     

84,749

  Depreciation and amortization

31,496

 

(585)

     

30,911

        Total costs and expenses

592,466

 

(6,013)

 

-

 

586,453

               

Income from operations

51,510

 

6,013

 

-

 

57,523

               

Other expense, net:

             

  Interest expense, net

1,004

         

1,004

  Foreign exchange transaction loss, net

694

         

694

  Gain on sale of investment

(707)

     

707

 

-

        Other expense, net

991

 

-

 

707

 

1,698

               

Income before taxes

50,519

 

6,013

 

(707)

 

55,825

               

Taxes on income

9,525

 

2,071

 

(247)

 

11,349

               

Net income 

$      40,994

 

$                3,942

 

$            (460)

 

$      44,476

               

Basic earnings per share

$          0.75

 

$                 0.07

 

$           (0.01)

 

$          0.81

               

Weighted average shares outstanding - basic

54,662,093

 

54,662,093

 

54,662,093

 

54,662,093

               

Diluted earnings per share

$          0.72

 

$                 0.07

 

$           (0.01)

 

$          0.78

               

Weighted average shares outstanding - diluted

56,880,115

 

56,880,115

 

56,880,115

 

56,880,115

               
               

(1) Represents costs incurred to better align capacity to preclinical market demand and reduce overall cost structure.

(2) Represents gain on sale of investment.

               

 

 

COVANCE INC.

 

GAAP to Pro Forma Reconciliation

 

YTD Q2 2014

 

(Dollars in thousands, except per share data)

 

(UNAUDITED)

               
     

Adjustments

 
 

GAAP

 

 Restructuring

and Other

Cost

Reduction

Activities (1)

 

Other
Items (2)

 

Pro Forma

               

Net revenues

$   1,259,508

         

$   1,259,508

Reimbursable out-of-pocket expenses

93,888

         

93,888

     Total revenues

1,353,396

 

-

 

-

 

1,353,396

               

Costs and expenses:

             

  Cost of revenue

879,212

         

879,212

  Reimbursable out-of-pocket expenses

93,888

         

93,888

  Selling, general and administrative

174,606

 

(7,504)

     

167,102

  Depreciation and amortization

66,974

 

(832)

     

66,142

  Impairment charges

52,564

     

(52,564)

 

-

        Total costs and expenses

1,267,244

 

(8,336)

 

(52,564)

 

1,206,344

               

Income from operations

86,152

 

8,336

 

52,564

 

147,052

               

Other expense, net:

             

  Interest expense, net

5,257

         

5,257

  Foreign exchange transaction loss, net

1,944

         

1,944

  Gain on sale of business

(1,648)

     

1,648

 

-

        Other expense, net

5,553

 

-

 

1,648

 

7,201

               

Income before taxes

80,599

 

8,336

 

50,916

 

139,851

               

Taxes on income

12,846

 

2,885

 

17,083

 

32,814

               

Net income 

$        67,753

 

$            5,451

 

$          33,833

 

$      107,037

               

Basic earnings per share

$            1.22

 

$              0.10

 

$              0.61

 

$            1.92

               

Weighted average shares outstanding - basic

55,618,752

 

55,618,752

 

55,618,752

 

55,618,752

               

Diluted earnings per share

$            1.17

 

$              0.09

 

$              0.59

 

$            1.85

               

Weighted average shares outstanding - diluted

57,769,847

 

57,769,847

 

57,769,847

 

57,769,847

               
               

(1) Represents costs incurred to better align capacity to preclinical market demand and reduce overall cost structure.

(2) Represents asset impairment charges $52,564 and gain on sale of business $1,648.

 

 

 

COVANCE INC.

 

GAAP to Pro Forma Reconciliation

 

YTD Q2 2013

 

(Dollars in thousands, except per share data)

 

(UNAUDITED)

               
     

Adjustments

 
 

GAAP

 

 Restructuring

and Other Cost

Reduction

Activities (1)

 

Other
Items (2)

 

Pro Forma

               

Net revenues

$  1,172,497

         

$  1,172,497

Reimbursable out-of-pocket expenses

105,814

         

105,814

     Total revenues

1,278,311

 

-

 

-

 

1,278,311

               

Costs and expenses:

             

  Cost of revenue

830,459

         

830,459

  Reimbursable out-of-pocket expenses

105,814

         

105,814

  Selling, general and administrative

179,396

 

(10,101)

     

169,295

  Depreciation and amortization

62,881

 

(2,082)

     

60,799

        Total costs and expenses

1,178,550

 

(12,183)

 

-

 

1,166,367

               

Income from operations

99,761

 

12,183

 

-

 

111,944

               

Other (income) expense, net:

             

  Interest expense, net

1,875

         

1,875

  Foreign exchange transaction loss, net

1,029

         

1,029

  Gain on sale of investments

(16,400)

     

16,400

 

-

        Other (income) expense, net

(13,496)

 

-

 

16,400

 

2,904

               

Income before taxes

113,257

 

12,183

 

(16,400)

 

109,040

               

Taxes on income

24,097

 

3,894

 

(5,746)

 

22,245

               

Net income 

$      89,160

 

$                8,289

 

$       (10,654)

 

$      86,795

               

Basic earnings per share

$          1.64

 

$                 0.15

 

$           (0.20)

 

$          1.59

               

Weighted average shares outstanding - basic

54,434,563

 

54,434,563

 

54,434,563

 

54,434,563

               

Diluted earnings per share

$          1.58

 

$                 0.15

 

$           (0.19)

 

$          1.53

               

Weighted average shares outstanding - diluted

56,598,936

 

56,598,936

 

56,598,936

 

56,598,936

               
               

(1) Represents costs incurred to better align capacity to preclinical market demand and reduce overall cost structure.

(2) Represents gain on sale of investments.

 

Suggested Articles

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.